tradingkey.logo
tradingkey.logo

Oncology Institute Inc

TOI
3.380USD
-0.010-0.29%
取引時間 ET15分遅れの株価
329.79M時価総額
損失額直近12ヶ月PER

Oncology Institute Inc

3.380
-0.010-0.29%

詳細情報 Oncology Institute Inc 企業名

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Oncology Institute Incの企業情報

企業コードTOI
会社名Oncology Institute Inc
上場日Mar 13, 2020
最高経営責任者「CEO」Virnich (Daniel)
従業員数825
証券種類Ordinary Share
決算期末Mar 13
本社所在地18000 Studebaker Rd
都市CERRITOS
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号90703
電話番号15627353226
ウェブサイトhttps://theoncologyinstitute.com/
企業コードTOI
上場日Mar 13, 2020
最高経営責任者「CEO」Virnich (Daniel)

Oncology Institute Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
--
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
事業別USD
会社名
収益
比率
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%

株主

更新時刻: Fri, Dec 5
更新時刻: Fri, Dec 5
株主統計
種類
株主統計
株主統計
比率
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
他の
79.09%
株主統計
株主統計
比率
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
他の
79.09%
種類
株主統計
比率
Investment Advisor
12.34%
Hedge Fund
11.00%
Investment Advisor/Hedge Fund
10.03%
Venture Capital
5.53%
Individual Investor
4.89%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
他の
50.68%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
2023Q2
180
58.28M
81.90%
-25.39M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
M33 Growth LLC
8.52M
9.12%
-5.15M
-37.65%
Sep 04, 2025
The Vanguard Group, Inc.
4.28M
4.58%
+2.53M
+144.52%
Jun 30, 2025
OncologyCare Partners LLC
4.11M
4.4%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.2%
+2.74M
+1088.12%
Jun 30, 2025
CenterBook Partners LP
715.90K
0.77%
+715.90K
--
Jun 30, 2025
Balyasny Asset Management LP
2.52M
2.69%
+371.00K
+17.28%
Jun 30, 2025
Wexford Capital LP
1.12M
1.2%
+1.12M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
1.37%
+893.70K
+231.68%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
比率0.11%
iShares Micro-Cap ETF
比率0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.03%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Oncology Institute Incの上位5名の株主は誰ですか?

Oncology Institute Incの上位5名の株主は以下のとおりです。
M33 Growth LLCは8.52M株を保有しており、これは全体の9.12%に相当します。
The Vanguard Group, Inc.は4.28M株を保有しており、これは全体の4.58%に相当します。
OncologyCare Partners LLCは4.11M株を保有しており、これは全体の4.40%に相当します。
Deerfield Management Company, L.P.は3.36M株を保有しており、これは全体の3.59%に相当します。
BlackRock Institutional Trust Company, N.A.は3.00M株を保有しており、これは全体の3.20%に相当します。

Oncology Institute Incの株主タイプ上位3種は何ですか?

Oncology Institute Incの株主タイプ上位3種は、
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC

Oncology Institute Inc(TOI)の株式を保有している機関の数はいくつですか?

2025Q3時点で、Oncology Institute Incの株式を保有している機関は145社あり、保有株式の総市場価値は約39.72Mで、全体の42.48%を占めています。2025Q2と比較して、機関の持ち株は-2.03%増加しています。

Oncology Institute Incの最大の収益源は何ですか?

FY2025Q2において、Dispensary revenue部門がOncology Institute Incにとって最大の収益を生み出しており、その金額は62.57Mで、全収益の52.23%を占めています。
KeyAI